Structure
Tofogliflozin hydrate, Inhibitor
Tofogliflozin hydrate
Purity
>98% (HPLC)
Synonyms
Tofogliflozin hydrate; CSG452 hydrate; CSG-452 hydrate; inhibitor
Purity/Purification
>98% (HPLC)
Suitability
10mM in DMSO
Target
SGLT
Receptor
SGLT
Chemical Name
Spiro[isobenzofuran-1(3H), 2'-[2H]pyran]-3', 4', 5'-triol, 6-[(4-ethylphenyl)methyl]-3', 4', 5', 6'-tetrahydro-6'-(hydroxymethyl)-, hydrate(1:1), (1S, 3'R, 4'S, 5'S, 6'R)
SMILES
CCC1=CC=C(C=C1)CC2=CC3=C(COC34C(C(C(C(O4)CO)O)O)O)C=C2.O
Molecular Formula
C22H28O7
CAS Number
1201913-82-7
Preparation and Storage
Store at -20 degree C
Stability: >=2 years
Shipping: Ice Pack
Stability: >=2 years
Shipping: Ice Pack
Structure
Structure
Related Product Information for Tofogliflozin hydrate, inhibitor
Tofogliflozin (CSG-452) is a potent, highly selective SGLT2 inhibitor with Ki of 2.9, 14.9, and 6.4nM against human, rat, and mouse SGLT2, respectively; displays high selectivity over human SGLT2 versus human SGLT1, SGLT6, and sodium/myo-inositol transporter 1; increases renal glucose clearance and lowered the blood glucose level in Zucker diabetic fatty rats, also improves postprandial glucose excursion; reduces glycated hemoglobin and improved glucose tolerance in the oral glucose tolerance test in vivo. Diabetes Approved
Product Categories/Family for Tofogliflozin hydrate, inhibitor
References
1. Suzuki M, et al. J Pharmacol Exp Ther. 2012 Jun; 341 (3):692-701.
2. Ohtake Y, et al. J Med Chem. 2012 Sep 13; 55 (17):7828-40.
3. Nagata T, et al. Am J Physiol Endocrinol Metab. 2013 Feb 15; 304 (4):E414-23.
4. Nagata T, et al. Br J Pharmacol. 2013 Oct; 170 (3):519-31.
2. Ohtake Y, et al. J Med Chem. 2012 Sep 13; 55 (17):7828-40.
3. Nagata T, et al. Am J Physiol Endocrinol Metab. 2013 Feb 15; 304 (4):E414-23.
4. Nagata T, et al. Br J Pharmacol. 2013 Oct; 170 (3):519-31.
Similar Products
Product Notes
The Tofogliflozin hydrate (Catalog #AAA3600727) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "Tofogliflozin hydrate, Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
